Aduro Biotech has announced the opening of a new corporate office and laboratory facility, which will serve as the company’s new global headquarters for its U.S. and European operations.

“Over the course of the last two years, we have grown significantly, both in the number of programs and in our employee base, and we have outgrown our former location,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “We are extremely pleased to remain in Berkeley, maintaining our roots and our key connections with both the University of California, Berkeley and this extraordinary community. Our new facility also provides room to grow as we continue to advance our three technology platforms focused on the development of immunotherapies that transform the treatment of challenging diseases.”

Aduro recently moved into the 110,853-square foot building at 740 Heinz Avenue, in the 17-building Aquatic Park Center R&D campus in West Berkeley.

“Technology and innovation are helping to drive our economy forward. As these new technologies are applied to healthcare, they are helping people live longer, healthier lives. I am pleased to know Aduro Biotech, a cutting-edge leader in immunotherapy, will remain in Berkeley and continue the East Bay’s tradition of world-leading innovation in healthcare and biotech,” said Congresswoman Barbara Lee.

Aduro Biotech is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including pancreatic, ovarian, lung and prostate cancers, mesothelioma and glioblastoma. Aduro's STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response.